GlassScriptPhysician profile
Andrew Sherman
NPI 1730700451
$4,787.36
in general payments reported to CMS, 2019-2025
27 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $580 · 2024: $1,985 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,571 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,570.98 |
| Education | $216.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $804.43 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Ensite |
| Amgen INC. | $629.79 | 2023-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $540.93 | 2024-2025 | Assure Wcd |
| Chiesi USA, INC. | $399.59 | 2023-2025 | Kengreal, Cleviprex |
| Inari Medical, INC. | $338.15 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $205.65 | 2025 | Avvigo Guidance System, Rotapro, Farapulse |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.77 | 2023-2024 | Lifevest |
| Stryker Corporation | $170.60 | 2025 | Artix Mt, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $161.50 | 2023-2025 | |
| Shockwave Medical, INC | $152.81 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $142.57 | 2024 | Penumbra System |
| Medtronic, INC. | $136.24 | 2024-2025 | In.Pact Admiral, Penditure, Symplicity G3 |
| Janssen Pharmaceuticals, INC | $134.00 | 2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $122.20 | 2024 | Optimizer |
| Novartis Pharmaceuticals Corporation | $95.42 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $92.14 | 2023-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $76.08 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $72.29 | 2023-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $64.29 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $51.09 | 2024-2025 | Wainua |
| Cardiva Medical, INC. | $47.28 | 2024 | Optowire |
| Lexicon Pharmaceuticals, INC. | $38.28 | 2023 | Inpefa |
| United Therapeutics Corporation | $33.98 | 2024 | Tyvaso |
| Reflow Medical INC | $23.71 | 2025 | |
| Teleflex LLC | $19.70 | 2025 | Guideliner |
| Lantheus Medical Imaging, INC. | $17.10 | 2023 | Definity |
| Janssen Scientific Affairs, LLC | $13.77 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.